February 5, 2021

February 9, 2021 – UNIONDALE, N.Y., (GLOBE NEWSWIRE) — Angion Biomedica Corp. (Angion) (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases, today announced the closing of $117 million in gross proceeds from its previously announced initial public offering and concurrent private placement. FLG partners Greg Curhan assisted.

Read the full release.